LYMPHANGIOLEIOMYOMATOSIS (LAM)
Clinical trials for LYMPHANGIOLEIOMYOMATOSIS (LAM) explained in plain language.
Never miss a new study
Get alerted when new LYMPHANGIOLEIOMYOMATOSIS (LAM) trials appear
Sign up with your email to follow new studies for LYMPHANGIOLEIOMYOMATOSIS (LAM), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Could a leukemia drug help treat a rare lung disease? new trial aims to find out
Disease control Recruiting nowThis study tests the long-term safety of imatinib, a drug already approved for leukemia, in women with lymphangioleiomyomatosis (LAM), a rare cystic lung disease. About 20 women aged 18-64 will receive either imatinib or a placebo for 6 months. The goal is to see if imatinib is s…
Matched conditions: LYMPHANGIOLEIOMYOMATOSIS (LAM)
Phase: PHASE1 • Sponsor: Columbia University • Aim: Disease control
Last updated May 26, 2026 12:05 UTC
-
Tiny blood clues could unlock secrets of rare lung disease
Knowledge-focused Recruiting nowThis study looks at tiny particles called extracellular vesicles in the blood of women with a rare lung disease called LAM, which can occur alone or with TSC. Researchers want to see if these particles can serve as biomarkers to help understand and track the disease. About 80 wom…
Matched conditions: LYMPHANGIOLEIOMYOMATOSIS (LAM)
Sponsor: University of Milan • Aim: Knowledge-focused
Last updated May 26, 2026 12:12 UTC